jili369 review ROME, Ga. — A motorist was killed as police responded to a bomb threat at the Georgia home of U.S. Rep. Marjorie Taylor Greene, authorities said. A police officer on the local bomb squad was traveling to the scene when he collided with another car on Monday, Rome police said in a statement. Greene identified the woman killed as Tammie Pickelsimer. The emailed threat — which warned of a pipe bomb in Greene’s mailbox and referenced Palestine — was sent to the assistant police chief. That touched off the police response, Greene said on social media. The source of the email was traced to a Russian internet address, she added. It was the latest instance of a crime known as “swatting” in which false threats are made to draw first responders to her home, Greene said. She said it has happened to her at least nine times. “These violent political threats have fatal consequences,” Greene said on the social media platform X, calling the crime a “despicable act.” “The perpetrator of this crime has committed murder in our small community of Rome, Georgia,” she added. The police officer was driving his personal vehicle to join the bomb squad on the call, police said. The officer was injured in the wreck, but the extent of his injuries was not immediately known Tuesday. “I’m sick to my stomach, but I’m also angry,” Greene said. “This should have never happened and I pray it never happens again.”Himax Technologies: Current Headwinds Hide A Bright Future

Title: Young People Revamp Down Jackets and Save Thousands, A New Trend of Saving Money and Staying Fashionable Cowboys G Zack Martin, CB Trevon Diggs out vs. Commanders

US President-elect Donald Trump's proposals to impose sweeping tariffs on imports could counter earlier efforts to cool inflation, Treasury Secretary Janet Yellen said Tuesday, warning that consumer prices could rise. Her comments at the Wall Street Journal's CEO Council Summit come as Trump has vowed broad tariffs of at least 10 percent on all imports, and higher rates on goods from China, Canada and Mexico. Imposing broad-based tariffs could "raise prices significantly for American consumers and create cost pressures on firms" which rely on imported goods, Yellen said when asked about Trump's plans. She cautioned that this could weigh on the competitiveness of certain sectors and increase costs to households. "This is a strategy I worry could derail the progress that we've made on inflation, and have adverse consequences on growth," she said. But she defended efforts by President Joe Biden's administration to impose targeted tariffs on Chinese goods to counter unfair trade practices by Beijing. She has previously raised concern over China's industrial overcapacity -- which risks a flood of underpriced goods into global markets and could undermine the development of key US industries. On Tuesday, Yellen also expressed regret that the United States has not made more progress on the country's deficit, saying she believes it "needs to be brought down, especially now that we're in an environment of higher interest rates." She stressed the importance of an independent Federal Reserve too, saying that countries perform better economically when central banks are allowed to exercise their best judgment without political influence. Trump has said that he would like "at least" a say over setting the Fed's interest rate. "I think it's a mistake to become involved in commenting on the Fed and certainly taking steps to compromise its independence," said Yellen. "I believe it tends to undermine the confidence of financial markets and, ultimately, of Americans in an important institution," she added. Yellen noted that she has spoken with Trump's Treasury chief nominee, billionaire hedge fund manager Scott Bessent, congratulating him on his nomination. bys/bjt

The successful completion of the 1 trillion yuan special national bonds arrangement sends a strong signal to the market about China's commitment to driving economic transformation and promoting innovation-led growth. It highlights the government's proactive approach to financing key strategic industries and fostering the development of emerging sectors that will shape the future of the Chinese economy.Deckers Stock, Two Others Break Out To New HighsQuebec Liberal Party leadership candidate Pablo Rodriguez received several new endorsements Sunday, including La Pinière MNA Linda Caron and Mont-Royal-Outremont MNA Michelle Setlakwe. Rodriguez named Caron as senior advisor responsible for social services and Setlakwe as co-chair of his campaign. He announced his candidacy for PLQ leadership in September and was formerly the federal Transport Minister. He has since received several endorsement, including from former ministers in the Bourassa and Couillard governments. The leadership election will take place in June 2025. The other candidates include Frédéric Beauchemin, Marc Bélanger, Denis Coderre and Charles Milliard.

The emergence of 3D-printed guns as a potential weapon in this high-profile crime has reignited the debate over gun control and the dangers posed by unregulated access to firearms. Unlike traditional firearms, 3D-printed guns can be manufactured using readily available materials and designs obtained online, making them a favored choice for individuals seeking to bypass gun laws and evade detection.

None

NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS) (the "Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it has drawn down the final tranche of €5 million ("Tranche C”) under the credit facility agreement for up to €40 million entered into with the European Investment Bank (the "EIB) on December 28, 2022 (the "Finance Contract"). With the drawdown of Tranche C, the Company has drawn down the full €40 million available under the Finance Contract. Tranche C is expected to be disbursed by the EIB by December 18, 2024. The Company plans to use the proceeds of Tranche C towards the development of its pipeline of allogeneic CAR T-cell product candidates: UCART22 and UCART20x22. As a condition to the disbursement of Tranche C the Company issued 611,426 warrants to the benefit of the EIB, in accordance with the terms of the 14 th resolution of the shareholders' meeting held on June 28, 2024 and articles L. 228-91 and seq. of the French Commercial Code (the "Tranche C Warrants”). Each Tranche C Warrant allows the EIB to subscribe for one ordinary share of the Company, at a price of €1.70, corresponding to 99% of the volume-weighted average price of the Company's ordinary shares over the last 3 trading days preceding the decision of the board of directors of the Company to issue the Tranche C Warrants. The total number of shares issuable upon exercise of the Tranche C Warrants represent circa 0.6% of the Company's outstanding share capital as at their issuance date. Tranche C will mature six years from its disbursement date and will accrue interest at a rate of 6% per annum capitalized annually and payable at maturity. The other terms of the Tranche C Warrants and prepayment events of Tranche C under the Finance Contract are as set forth in the Company's press release of April 4, 2023 and Form 6-K filed with the U.S. Securities and Exchange Commission on such date. About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with 25 years of experience and expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN ® , its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. Cellectis' headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit our website: www.cellectis.com Follow Cellectis on social networks @cellectis on LinkedIn and X (formerly Twitter) TALEN® is a registered trademark owned by Cellectis. Cautionary Statement This press release contains "forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as "expect,” "plan,” and "will,” or the negative of these and similar expressions. These forward-looking statements, which are based on our management's current expectations and assumptions and on information currently available to management. Forward-looking statements include statements about the date of disbursement of the Tranche C and the use of the proceeds of amounts received under the Finance Contract. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the numerous risks associated with market conditions, and our ability to satisfy the conditions precedent under the Finance Contract. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F as amended and in our annual financial report (including the management report) for the year ended December 31, 2023 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, which are available on the SEC's website at www.sec.gov , as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future. For further information on Cellectis, please contact: Media contacts: Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, [email protected] Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93 Investor Relations contact: Arthur Stril, Interim Chief Financial Officer, [email protected] AttachmentThe response to the call for adoption has been nothing short of inspiring, with countless individuals stepping up to offer a second chance to these loyal and hardworking search and rescue dogs. The bond between humans and animals is a powerful one, and the willingness of so many to embrace these dogs in their time of need exemplifies the compassion and kindness that exists within our communities.Just A Month Before Christmas, Amazon Has Slashed The Price of The PS5 Slim to a New Record Low